Clinical Trial Update: A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating adjuvant erlotinib after surgical resection with or without chemotherapy in EGFR-positive non-small cell lung cancer; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-06-03